Monte Rosa Therapeutics (GLUE) Total Non-Current Liabilities (2020 - 2026)

Monte Rosa Therapeutics (GLUE) posted quarterly Total Non-Current Liabilities of $10.5 million for Q1 2026, down 13.22% quarter-over-quarter from $12.1 million in Q4 2025.

Monte Rosa Therapeutics (GLUE) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Monte Rosa Therapeutics' Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $10.5 million for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (changed N/A YoY), while the FY2025 annual figure was $12.1 million, changed N/A from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $10.5 million, down from $12.1 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $101.2 million in Q3 2025, with the low at $10.5 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Monte Rosa Therapeutics 1.32 Bn 688.11 Mn - 99.70 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 99.70 Mn
Mar 31, 2026 10.50 Mn
Dec 31, 2025 12.10 Mn
Sep 30, 2025 101.20 Mn
Dec 31, 2021 18.81 Mn
Sep 30, 2021 14.74 Mn
Jun 30, 2021 12.26 Mn
Dec 31, 2020 -37.42 Mn